Abstract
Luminal A breast cancer can present with early, unexpected lymph node metastasis, and sentinel lymph node biopsy has been reported false negative in some cases. We aimed to construct a biomarker-based model that predicts lymph node metastasis in luminal A breast cancer, using expression of silent mating type information regulation 2 homolog 1 (SIRT1) and apoptosis-related factors, which are known to be closely related. We selected tissue samples of 278 cases of luminal A invasive ductal carcinoma, constructed tissue microarrays, and performed immunohistochemical staining for SIRT1 and four apoptosis-related proteins. In constructing the best predictive model for lymph node metastasis, six clinicopathological parameters and five molecular markers were considered. Independent factors predictive of lymph node metastasis were pT stage (OR 1.829, p = 0.027), lymphovascular invasion (OR 4.128, p < 0.001), and decreased expression of caspase-3 (OR 0.535, p = 0.034) and of SIRT1 (OR 0.526, p = 0.053). A combination nuclear grade, lymphovascular invasion, increased B-cell lymphoma 2 (Bcl-2) expression, and reduced expression of caspase-3 and of SIRT1 yielded the strongest predictive performance for lymph node metastasis with an area under the curve (AUC) of 0.696. This combination was also predictive of shortened disease-free survival (73.1 vs. 67.7 months, p = 0.003). Our data support a role of SIRT1 protein as tumor suppressor in luminal A breast cancer, in association with apoptosis-related proteins. Our model based upon a combination of these biomarkers is expected to increase accuracy of prediction of lymph node metastasis in luminal A breast cancer. This might serve as a valuable tool in determining the optimal surgical strategy in breast cancer patients.
Similar content being viewed by others
References
Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lonning PE, Borresen-Dale AL (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869–10874
Gulben K, Berberoglu U, Aydogan O, Kinas V (2014) Subtype is a predictive factor of nonsentinel lymph node involvement in sentinel node-positive breast cancer patients. J Breast Cancer 17:370–375
Sawaki M, Idota A, Ichikawa M, Gondo N, Horio A, Kondo N, Hattori M, Fujita T, Yatabe Y, Iwata H (2014) Impact of intrinsic subtype on predicting axillary lymph node metastasis in breast cancer. Oncol Lett 8:1707–1712
Ernst MF, Voogd AC, Balder W, Klinkenbijl JH, Roukema JA (2002) Early and late morbidity associated with axillary levels I-III dissection in breast cancer. J Surg Oncol 79:151–155
Chao C, Wong SL, Woo C, Edwards MJ, Tuttle T, Noyes RD, Carlson DJ, Turk P, Simpson D, McMasters KM (2001) Reliable lymphatic drainage to axillary sentinel lymph nodes regardless of tumor location within the breast. Am J Surg 182:307–311
Song NY, Surh YJ (2012) Janus-faced role of SIRT1 in tumorigenesis. Ann N Y Acad Sci 1271:10–19
Yuan H, Su L, Chen WY (2013) The emerging and diverse roles of sirtuins in cancer: a clinical perspective. Onco Targets Ther 6:1399–1416
Lee H, Kim KR, Noh SJ, Park HS, Kwon KS, Park BH, Jung SH, Youn HJ, Lee BK, Chung MJ, Koh DH, Moon WS, Jang KY (2011) Expression of DBC1 and SIRT1 is associated with poor prognosis for breast carcinoma. Hum Pathol 42:204–213
Suzuki K, Hayashi R, Ichikawa T, Imanishi S, Yamada T, Inomata M, Miwa T, Matsui S, Usui I, Urakaze M, Matsuya Y, Ogawa H, Sakurai H, Saiki I, Tobe K (2012) SRT1720, a SIRT1 activator, promotes tumor cell migration, and lung metastasis of breast cancer in mice. Oncol Rep 27:1726–1732
Kuo SJ, Lin HY, Chien SY, Chen DR (2013) SIRT1 suppresses breast cancer growth through downregulation of the Bcl-2 protein. Oncol Rep 30:125–130
Moore RL, Faller DV (2013) SIRT1 represses estrogen-signaling, ligand-independent ER alpha-mediated transcription, and cell proliferation in estrogen-responsive breast cells. J Endocrinol 216:273–285
Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lonning PE, Brown PO, Borresen-Dale AL, Botstein D (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100:8418–8423
Yoo SH, Park IA, Chung YR, Kim H, Lee K, Noh DY, Im SA, Han W, Moon HG, Lee KH, Ryu HS (2015) A histomorphologic predictive model for axillary lymph node metastasis in preoperative breast cancer core needle biopsy according to intrinsic subtypes. Hum Pathol 46:246–254
Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thurlimann B, Senn HJ (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013. Ann Oncol 24:2206–2223
Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403–410
Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC (2010) American society of clinical oncology/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784–2795
Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of American pathologists clinical practice guideline update. J Clin Oncol 31:3997–4013
Agarwal A, Mahfouz RZ, Sharma RK, Sarkar O, Mangrola D, Mathur PP (2009) Potential biological role of poly (ADP-ribose) polymerase (PARP) in male gametes. Reprod Biol Endocrinol 7:143
Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG (2010) PARP inhibition: PARP1 and beyond. Nat Rev Cancer 10:293–301
Kim TH, Kim HS, Kang YJ, Yoon S, Lee J, Choi WS, Jung JH (2015) Psammaplin A induces Sirtuin 1-dependent autophagic cell death in doxorubicin-resistant MCF-7/adr human breast cancer cells and xenografts. Biochim Biophys Acta 1850:401–410
Wang T, Cui H, Ma N, Jiang Y (2013) Nicotinamide-mediated inhibition of SIRT1 deacetylase is associated with the viability of cancer cells exposed to antitumor agents and apoptosis. Oncol Lett 6:600–604
Scomersi S, Torelli L, Zanconati F, Tonutti M, Dore F, Bortul M (2012) Evaluation of a breast cancer nomogram for predicting the likelihood of additional nodal metastases in patients with a positive sentinel node biopsy. Ann Ital Chir 83:461–468
Cho J, Han W, Lee JW, Ko E, Kang SY, Jung SY, Kim EK, Moon WK, Cho N, Park IA, Chung JK, Hwang KT, Kim SW, Noh DY (2008) A scoring system to predict nonsentinel lymph node status in breast cancer patients with metastatic sentinel lymph nodes: a comparison with other scoring systems. Ann Surg Oncol 15:2278–2286
Barras D, Lorusso G, Lhermitte B, Viertl D, Ruegg C, Widmann C (2014) Fragment N2, a caspase-3-generated RasGAP fragment, inhibits breast cancer metastatic progression. Int J Cancer 135:242–247
Mi C, Shi H, Ma J, Han LZ, Lee JJ, Jin X (2014) Celastrol induces the apoptosis of breast cancer cells and inhibits their invasion via downregulation of MMP-9. Oncol Rep 32:2527–2532
Kim EJ, Hong JE, Eom SJ, Lee JY, Park JH (2011) Oral administration of benzyl-isothiocyanate inhibits solid tumor growth and lung metastasis of 4T1 murine mammary carcinoma cells in BALB/c mice. Breast Cancer Res Treat 130:61–71
Elangovan S, Ramachandran S, Venkatesan N, Ananth S, Gnana-Prakasam JP, Martin PM, Browning DD, Schoenlein PV, Prasad PD, Ganapathy V, Thangaraju M (2011) SIRT1 is essential for oncogenic signaling by estrogen/estrogen receptor alpha in breast cancer. Cancer Res 71:6654–6664
Chung YR, Kim H, Park SY, Park IA, Jang JJ, Choe JY, Jung YY, Im SA, Moon HG, Lee KH, Suh KJ, Kim TY, Noh DY, Han W, Ryu HS (2015) Distinctive role of SIRT1 expression on tumor invasion and metastasis in breast cancer by molecular subtype. Hum Pathol
Simic P, Williams EO, Bell EL, Gong JJ, Bonkowski M, Guarente L (2013) SIRT1 suppresses the epithelial-to-mesenchymal transition in cancer metastasis and organ fibrosis. Cell Rep 3:1175–1186
Scuto A, Kirschbaum M, Buettner R, Kujawski M, Cermak JM, Atadja P, Jove R (2013) SIRT1 activation enhances HDAC inhibition-mediated upregulation of GADD45G by repressing the binding of NF-κB/STAT3 complex to its promoter in malignant lymphoid cells. Cell Death Dis 16(4), e635
Acknowledgments
This study was supported by Grant No. 04-2013-0840 from Seoul National University Hospital Research Fund.
Conflict of interest
The authors declare that they have no competing interests.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Han Suk Ryu and Seock-Ah Im evenly contributed to this work as co-corresponding authors.
Hyojin Kim and Kyung-Hun Lee evenly contributed to this work as co-first authors.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Supplementary Fig. 1
(A&B) Comparison of disease-free survival for low and high risk groups according to the use of postoperative adjuvant chemotherapy. (C&D) Comparison of disease-free survival for low and high risk groups according to the use of postoperative adjuvant hormone receptor blockers (JPEG 638 kb)
Rights and permissions
About this article
Cite this article
Kim, H., Lee, KH., Park, I.A. et al. Expression of SIRT1 and apoptosis-related proteins is predictive for lymph node metastasis and disease-free survival in luminal A breast cancer. Virchows Arch 467, 563–570 (2015). https://doi.org/10.1007/s00428-015-1815-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00428-015-1815-7